AVVAA World Health Care Products, Inc. (AVVH)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | 0 | 0 | 0 | 0 | - | - |
| Operating profit | $m | -0 | - | ||||||
| Net profit | $m | - | - | -0 | -0 | -0 | -0 | - | - |
| EPS reported | $ | 0.00 | - | ||||||
| Operating cashflow per share | $ | -0.00 | - | ||||||
| Capex per share | $ | 0.00 | - | ||||||
| FCF per share | $ | -0.00 | - | ||||||
| Free cash flow | $m | -0 | - | ||||||
| Net debt | $m | 0 | - | ||||||
| Book value equity | $m | -0 | - | ||||||
| Book value per share | $ | -0.00 | - | ||||||
| Number of shares | m | 966.44 | - | ||||||
| DPS (TTM paid) | $ | 0.00 | - |
Financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -94.12 | - | ||||||
| P/S LTM | x | 831.35 | - | ||||||
| P/FCF LTM | x | -15.71 | - | ||||||
| EV/EBITDA LTM | x | -118.19 | - | ||||||
| EV/Sales LTM | x | 882.57 | - | ||||||
| Earnings Yield LTM | % | -1.01% | - | ||||||
| FCF Yield | % | -6.36% | - | ||||||
| Quality | |||||||||
| ROE | % | +95.25% | - | ||||||
| ROIC | % | -16.62% | - | ||||||
| Operating margin | % | -7.47% | - | ||||||
| Gross margin | % | +32.71% | - | ||||||
| FCF/Sales | % | -5290.5% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | -0.98 | - | ||||||
| Net Debt/EBITDA | x | -6.86 | - | ||||||
| EBIT/Net interest | x | -7.89 | - | ||||||
| Net debt/market cap | % | +6.47% | - | ||||||
| Net debt/Equity | x | -5.80 | - | ||||||
| Gross debt/equity | x | -6.09 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
AVVAA World Health Care Products, Inc. operates as a global biotechnology firm, specializing in natural and therapeutic personal care solutions. Its primary endeavor involves the development, manufacturing, and mass-market distribution of the over-the-counter Neuroskin product line. These treatments are formulated to address various skin irregularities and promote the natural clarity and texture of healthy skin, reaching consumers through conventional food and drug channels. Beyond its own brands, AVVAA also possesses distribution rights for a range of patented European skincare items. These scientifically-backed formulations target the symptoms of persistent dermatological conditions such as eczema, psoriasis, and acne. Diversifying its portfolio, the company extends its natural care offerings to animals, providing grooming treatments for a variety of pets including dogs, cats, and horses. Established in 1998 and headquartered in Richmond, Virginia, AVVAA has been a subsidiary of Gold Quest Capital, Inc. since June 23, 2021.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
AVVAA World Health Care Products, Inc. (AVVH)
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
AVVAA World Health Care Products, Inc. operates as a global biotechnology firm, specializing in natural and therapeutic personal care solutions. Its primary endeavor involves the development, manufacturing, and mass-market distribution of the over-the-counter Neuroskin product line. These treatments are formulated to address various skin irregularities and promote the natural clarity and texture of healthy skin, reaching consumers through conventional food and drug channels. Beyond its own brands, AVVAA also possesses distribution rights for a range of patented European skincare items. These scientifically-backed formulations target the symptoms of persistent dermatological conditions such as eczema, psoriasis, and acne. Diversifying its portfolio, the company extends its natural care offerings to animals, providing grooming treatments for a variety of pets including dogs, cats, and horses. Established in 1998 and headquartered in Richmond, Virginia, AVVAA has been a subsidiary of Gold Quest Capital, Inc. since June 23, 2021.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free